OBJECTIVE: Late-onset neutropenia (LON) is an underrecognized complication of rituximab treatment. We undertook this study to describe its incidence, risk factors, clinical features, management, and recurrence. METHODS: We conducted a single-center retrospective cohort study of 738 adult patients with autoimmune disease who were treated with rituximab to induce continuous B cell depletion. The primary outcome measure was LON, defined as an unexplained absolute neutrophil count of <1,000 cells/µl during B cell depletion. Secondary outcome measures included incidental diagnosis, fever, sepsis, filgrastim use, and recurrent LON. We assessed predictors of LON using Cox proportional hazards regression models. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: We identified 107 episodes of LON in 71 patients. The cumulative incidence at 1 year of B cell depletion therapy was 6.6% (95% CI 5.0-8.7). The incidence rate during the first year was higher compared to thereafter (7.2 cases per 100 person-years [95% CI 5.4-9.6] versus 1.5 cases per 100 person-years [95% CI 1.0-2.3]). Systemic lupus erythematosus and combination therapy with cyclophosphamide were each independently associated with an increased risk of LON (adjusted HR 2.96 [95% CI 1.10-8.01] and 1.98 [95% CI 1.06-3.71], respectively). LON was not observed in minimal change disease or focal segmental glomerulosclerosis. The majority of episodes (59.4%) were asymptomatic. Fever and sepsis complicated 31.3% and 8.5% of episodes, respectively. Most patients (69%) were treated with filgrastim. Rituximab rechallenge occurred in 87% of patients, of whom 21% developed recurrent LON. CONCLUSION: LON is common and often incidental. Most cases are reversible and respond well to filgrastim. However, LON can be associated with serious infections and thus warrants vigilant monitoring.
OBJECTIVE: Late-onset neutropenia (LON) is an underrecognized complication of rituximab treatment. We undertook this study to describe its incidence, risk factors, clinical features, management, and recurrence. METHODS: We conducted a single-center retrospective cohort study of 738 adult patients with autoimmune disease who were treated with rituximab to induce continuous B cell depletion. The primary outcome measure was LON, defined as an unexplained absolute neutrophil count of <1,000 cells/µl during B cell depletion. Secondary outcome measures included incidental diagnosis, fever, sepsis, filgrastim use, and recurrent LON. We assessed predictors of LON using Cox proportional hazards regression models. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: We identified 107 episodes of LON in 71 patients. The cumulative incidence at 1 year of B cell depletion therapy was 6.6% (95% CI 5.0-8.7). The incidence rate during the first year was higher compared to thereafter (7.2 cases per 100 person-years [95% CI 5.4-9.6] versus 1.5 cases per 100 person-years [95% CI 1.0-2.3]). Systemic lupus erythematosus and combination therapy with cyclophosphamide were each independently associated with an increased risk of LON (adjusted HR 2.96 [95% CI 1.10-8.01] and 1.98 [95% CI 1.06-3.71], respectively). LON was not observed in minimal change disease or focal segmental glomerulosclerosis. The majority of episodes (59.4%) were asymptomatic. Fever and sepsis complicated 31.3% and 8.5% of episodes, respectively. Most patients (69%) were treated with filgrastim. Rituximab rechallenge occurred in 87% of patients, of whom 21% developed recurrent LON. CONCLUSION: LON is common and often incidental. Most cases are reversible and respond well to filgrastim. However, LON can be associated with serious infections and thus warrants vigilant monitoring.
Authors: D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy Journal: Blood Date: 1997-09-15 Impact factor: 22.113
Authors: Kieron Dunleavy; Frances Hakim; Hyun Kyung Kim; John E Janik; Nicole Grant; Takayuki Nakayama; Therese White; George Wright; Larry Kwak; Ronald Gress; Giovanna Tosato; Wyndham H Wilson Journal: Blood Date: 2005-02-17 Impact factor: 22.113
Authors: P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: William F Pendergraft; Frank B Cortazar; Julia Wenger; Andrew P Murphy; Eugene P Rhee; Karen A Laliberte; John L Niles Journal: Clin J Am Soc Nephrol Date: 2014-03-13 Impact factor: 8.237
Authors: J H Salmon; P Cacoub; B Combe; J Sibilia; B Pallot-Prades; O Fain; A Cantagrel; M Dougados; E Andres; O Meyer; P Carli; E Pertuiset; I Pane; F Maurier; P Ravaud; X Mariette; J E Gottenberg Journal: RMD Open Date: 2015-06-30
Authors: Philipp Gauckler; Jae Il Shin; Federico Alberici; Vincent Audard; Annette Bruchfeld; Martin Busch; Chee Kay Cheung; Matija Crnogorac; Elisa Delbarba; Kathrin Eller; Stanislas Faguer; Kresimir Galesic; Siân Griffin; Martijn W F van den Hoogen; Zdenka Hrušková; Anushya Jeyabalan; Alexandre Karras; Catherine King; Harbir Singh Kohli; Gert Mayer; Rutger Maas; Masahiro Muto; Sergey Moiseev; Balazs Odler; Ruth J Pepper; Luis F Quintana; Jai Radhakrishnan; Raja Ramachandran; Alan D Salama; Ulf Schönermarck; Mårten Segelmark; Lee Smith; Vladimír Tesař; Jack Wetzels; Lisa Willcocks; Martin Windpessl; Ladan Zand; Reza Zonozi; Andreas Kronbichler Journal: Kidney Int Rep Date: 2021-01-13
Authors: Balazs Odler; Martin Windpessl; Marcell Krall; Maria Steiner; Regina Riedl; Carina Hebesberger; Martin Ursli; Emanuel Zitt; Karl Lhotta; Marlies Antlanger; Daniel Cejka; Philipp Gauckler; Martin Wiesholzer; Marcus Saemann; Alexander R Rosenkranz; Kathrin Eller; Andreas Kronbichler Journal: Front Immunol Date: 2021-10-29 Impact factor: 7.561